

Cardiac Pharmacology

Edited by

R. DOUGLAS WILKERSON

Cardiac Pharmacology

Edited by

R. DOUGLAS WILKERSON

Department of Pharmacology and Therapeutics
Medical College of Ohio
Toledo, Ohio

1981



ACADEMIC PRESS

A Subsidiary of Harcourt Brace Jovanovich, Publishers
New York London Toronto Sydney San Francisco

一九八三年十月十五日

COPYRIGHT © 1981, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.

111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by

ACADEMIC PRESS, INC. (LONDON) LTD.

24/28 Oval Road, London NW1 7DX

Library of Congress Cataloging in Publication Data

Main entry under title:

Cardiac pharmacology.

(Physiologic and pharmacologic bases of drug therapy)

Bibliography: p.

Includes index.

1. Heart--Effect of drugs on. 2. Cardiovascular agents--Physiological effect. I. Wilkerson, R. Douglas.

II. Series. [DNLM: 1. Cardiovascular agents--Pharmacodynamics. 2. Cardiovascular diseases--Drug therapy. QV 150 C264]

RM345.C35 615'.71

81-12873

ISBN 0-12-752050-3

AACR2

PRINTED IN THE UNITED STATES OF AMERICA

81 82 83 84 9 8 7 6 5 4 3 2 1

List of Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

Theodore M. Brody (95), Department of Pharmacology, Michigan State University, East Lansing, Michigan 48824

Mary L. Bush (53), Department of Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425

Kanu Chatterjee (149), Department of Medicine, Cardiovascular Division, Moffitt Hospital, University of California, San Francisco, School of Medicine, San Francisco, California 94143

Peter Danilo, Jr. (275), Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032

James E. Doherty (127), Veterans Administration Hospital, Little Rock, Arkansas 72206

James M. Downey (3, 361), Department of Physiology, College of Medicine, University of South Alabama, Mobile, Alabama 36688

David C. Gadsby (229), Laboratory of Cardiac Physiology, The Rockefeller University, New York, New York 10021

William J. George (75), Department of Pharmacology, School of Medicine, Tulane University, New Orleans, Louisiana 70112

Richard A. Gillis (25), Department of Pharmacology, School of Medicine and Dentistry, Georgetown University, Washington, D.C. 20007

Richard M. Graeff* (75), Department of Pharmacology, School of Medicine, Tulane University, New Orleans, Louisiana 70112

Ronald P. Karlsberg† (415), University of California, Irvine, Veterans Administration Medical Center, Long Beach, California 90822

*Present address: Department of Pharmacology, School of Medicine, University of Minnesota, Minneapolis, Minnesota 55455.

†Present address: Cardiology Division, Cedars-Sinai Medical Center, Los Angeles, California 90048.

- George K. Massing** (305), Department of Medicine, College of Medicine, University of South Alabama, Mobile, Alabama 36688
- Douglas F. Munch** (3, 361), Travenol Laboratories, Inc., Round Lake, Illinois 60073
- Walter H. Newman** (53), Department of Pharmacology, Medical University of South Carolina, Charleston, South Carolina 29425
- Thomas A. Ports** (149), Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco, California 94143
- B. N. C. Prichard** (387), Department of Clinical Pharmacology, School of Medicine, University College London, London WC1E 6JJ, England
- Jack K. Pruett** (209), Department of Anesthesiology, Medical College of Georgia, Augusta, Georgia 30901
- John A. Quest** (25), National Toxicology Program/NIEHS, National Institutes of Health, Bethesda, Maryland 20205
- Michael R. Rosen** (275), Departments of Pharmacology and Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New York 10032
- Michael J. Rovetto** (335), Department of Physiology, School of Medicine, University of Missouri, Columbia, Missouri 65201
- R. Douglas Wilkerson** (113), Department of Pharmacology and Therapeutics, Medical College of Ohio, Toledo, Ohio 43699
- Andrew L. Wit** (229), Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032

Preface

This volume "Cardiac Pharmacology" is intended to interface basic and clinical knowledge of those interventions used or being studied for use in the treatment of heart disease. The volume is divided into four major sections which address intrinsic and neural control of cardiac function, pharmacologic modification of cardiac contractility and cardiac output, the genesis and control of cardiac arrhythmias, and pharmacologic manipulation of myocardial oxygen supply and demand. A somewhat unique feature of this volume is that each of the last three sections contains a chapter describing the most up-to-date techniques employed in the study of that particular aspect of cardiac function and its alterations by pharmacologic interventions. Further, each section contains a blend of basic and clinical material written in such a way as to be useful to both the scientist in the laboratory and the clinician at the bedside. Although no single volume dealing with a topic as complex as the actions of drugs upon the heart can be all things to all people, this volume will be of value to anyone interested in the area of cardiovascular medicine. Undoubtedly, the greatest asset to this volume is the outstanding group of authors who have contributed. In addition to many established investigators whose names are readily recognizable, this group also includes a number of younger scientists and clinicians who are rapidly making a place for themselves in the areas of cardiac pharmacology, physiology, or cardiology.

I would like to express my gratitude to all of the individuals who have helped in the preparation of this book. Special thanks go to the secretarial staff of the Department of Pharmacology and Therapeutics at the Medical College of Ohio for their patient typing and retyping of many parts of the text and to my wife, Dottie, for invaluable assistance in indexing this volume.

R. Douglas Wilkerson

Contents

<i>List of Contributors</i>	xiii
-----------------------------	------

<i>Preface</i>	xv
----------------	----

I Intrinsic and Neural Control of Cardiac Function

1 Regulation of Myocardial Contractility

DOUGLAS F. MUNCH and JAMES M. DOWNEY

I. Contractility Defined	4
II. Neural Regulation of Cardiac Contractility	7
III. Humoral Regulation of Contractility	15
IV. Autoregulation	17
References	20

2 The Nervous System as an Important Site of Action for Drugs Affecting Cardiovascular Function

RICHARD A. GILLIS and JOHN A. QUEST

I. Introduction	25
II. Positive Inotropic Agents	27
III. Antiarrhythmic Agents	32
IV. Antihypertensive Agents	35
V. Antianginal Agents	42
VI. The Nervous System as a Target for Developing New and Better Therapies for Cardiovascular Disease	43
References	46

II Pharmacologic Modification of Cardiac Function

3 Evaluation of Drug-Induced Alterations in Myocardial Contractility

WALTER H. NEWMAN and MARY L. BUSH

I. Introduction	53
II. Conceptual Basis for Indices of Myocardial Contractility	54
III. Indices Obtained during the Isovolumic Phase of Ventricular Systole	61
IV. Indices Obtained during the Ejection Phase of Ventricular Systole	65
V. The Walton-Brodie Strain Gauge Arch	67
VI. Summary	71
References	72

4 Cyclic Nucleotides and Cardiac Function

WILLIAM J. GEORGE and RICHARD M. GRAEFF

I. Cyclic AMP	75
II. Cyclic GMP	79
III. Phosphodiesterase	82
IV. Effects of Hypoxia and Ischemia on Cyclic Nucleotide Content of the Heart	85
V. Cyclic Nucleotides and Coronary Vascular Function	86
VI. Cyclic Nucleotides and Cardiac Metabolism	87
References	91

5 Na⁺, K⁺-ATPase Activity and Cardiac Glycoside Action

THEODORE M. BRODY

I. Introduction	95
II. The Nature of the Enzyme	96
III. Theories on the Mechanism of Action of Cardiac Glycosides	99
IV. Digitalis Toxicity and Na ⁺ , K ⁺ -ATPase Activity	109
V. Conclusions	110
References	111

6 Effects of Digitalis Glycosides on Myocardial Function

R. DOUGLAS WILKERSON

I. Introduction	113
II. Inotropic Effects of Digitalis Glycosides	115

III. Cardiac Electrophysiologic Effects of Digitalis	119
IV. Digitalis Glycoside Toxicity	122
V. New Directions in Research on Positive Inotropic Agents	123
References	124

7 Clinical Pharmacology of Digitalis Glycosides

JAMES E. DOHERTY

I. Introduction	127
II. Pharmacokinetics of the Digitalis Glycosides	128
III. Serum Levels of Digitalis Glycosides	136
IV. Drug Interactions	143
V. Digitalis Intoxication	144
References	145

8 Physiologic and Pharmacologic Basis for the Use of Vasodilators in Heart Failure

KANU CHATTERJEE and THOMAS A. PORTS

I. Introduction	150
II. Mechanism of Action of Vasodilators	150
III. Afterload or Impedance Reduction	150
IV. Venodilation	157
V. Improvement in Segmental Myocardial Ischemia	157
VI. Left Ventricular Compliance	158
VII. Pathophysiology of Myocardial Failure	159
VIII. Classification of Vasodilators	161
IX. Hemodynamic Effects of Vasodilators	163
X. Clinical Use of Vasodilators in Heart Failure and Myocardial Infarction	170
XI. Summary	200
References	201

III Genesis and Control of Cardiac Arrhythmias

9 Electrophysiologic Evaluation of Potential Antiarrhythmic Drugs

JACK K. PRUETT

I. Introduction	209
II. Instrumentation	210
III. Isolated Tissues	215

IV. Membrane Potentials	219
V. Influence of Drugs and Chemicals on Cardiac Membrane Potentials	224
References	227
10 Electrophysiologic Characteristics of Cardiac Cells and the Genesis of Cardiac Arrhythmias	
DAVID C. GADSBY and ANDREW L. WIT	
I. Introduction	229
II. The Resting Potential of Cardiac Cells	230
III. Action Potentials in Cardiac Cells	238
IV. Effects of Disease on the Electrophysiologic Characteristics of Cardiac Cells	250
V. The Genesis of Cardiac Arrhythmias	254
References	271
11 Antiarrhythmic Drugs	
PETER DANILO, JR. and MICHAEL R. ROSEN	
I. Introduction	276
II. Quinidine, Procainamide, and Disopyramide	276
III. <i>N</i> -Acetylprocainamide	280
IV. Lidocaine, Tocainide, and Mexiletine	281
V. Phenytoin (Diphenylhydantoin)	285
VI. Propranolol	287
VII. Verapamil	291
VIII. Bretylium	294
IX. Aprindine	295
X. Amiodarone	297
XI. Conclusions	298
References	298
12 The Clinical Pharmacology of Antiarrhythmic Drugs	
GEORGE K. MASSING	
I. Introduction	305
II. Pharmacokinetics of Antiarrhythmic Drugs	306
III. Indications and End-Points for Antiarrhythmic Therapy	314
IV. Role of Electrophysiologic Studies to Determine the Efficacy of Antiarrhythmic Drugs	326
V. Blood Levels of Antiarrhythmic Drugs	327

VI. Summary	329
References	329

IV Pharmacologic Modification of Myocardial Oxygen Supply and Demand

13 Myocardial Metabolism

MICHAEL J. ROVETTO

I. Introduction	335
II. Control of Carbohydrate Utilization	336
III. Control of Fatty Acid Metabolism	342
IV. Interaction of Glucose and Fatty Acid Utilization	347
V. Effects of Cardiac Work on Substrate Utilization	348
VI. Effects of Hypoxia on Substrate Utilization	349
VII. Effects of Catecholamines on Substrate Utilization	351
VIII. Effects of Insulin on Myocardial Substrate Utilization	353
IX. Summary	354
References	355

14 Evaluation of Drug Effects on Coronary Blood Flow and Cardiac Oxygen Consumption

JAMES M. DOWNEY and DOUGLAS F. MUNCH

I. Choosing the Experimental Model	361
II. Methods for Measuring Coronary Flow	364
III. Collateral Blood Flow Measurements	377
IV. Measure of Myocardial Oxygen Consumption	381
References	383

15 β -Adrenergic Antagonists in Angina and Myocardial Infarction

B. N. C. PRICHARD

I. The Basis of the Use of β -Adrenergic Antagonists in Ischemic Heart Disease	388
II. Effect of β -Adrenergic Antagonists on Coronary Blood Flow	389
III. Effects of β -Adrenergic Antagonists on the Blood	390
IV. β -Adrenergic Antagonists in Angina Pectoris	391
V. Division I: Nonselective β -Adrenergic Antagonists	393
VI. Division II: Cardioselective β -Adrenergic Antagonists	396

VII.	Division III: Nonselective β -Adrenergic Antagonists Plus α Blockade	397
VIII.	Comparison of Adrenergic Blocking Drugs	397
IX.	β -Blocking Drugs in Combination with Other Antianginal Agents	400
X.	Withdrawal of β -Adrenergic Blocking Drugs in Patients with Angina Pectoris	401
XI.	Regulation of Dosage of β -Adrenergic Antagonists in Patients with Angina Pectoris	403
XII.	The Value of β -Adrenoceptor Antagonists in Angina Pectoris	404
XIII.	β -Adrenergic Antagonists in Myocardial Infarction	405
XIV.	Conclusion	408
	References	409
 16 Modification of Myocardial Infarct Size by Drugs: Methods for Measuring Infarct Size and Approach to Patient Care		
RONALD P. KARLSBERG		
I.	The Border Zone	416
II.	Techniques for Measuring the Extent of Damage	418
III.	Factors That Determine the Outcome of Ischemic Myocardium	427
IV.	The Treatment of Potential Detrimental Events	427
V.	The Treatment of the Uncomplicated Patient	430
VI.	Conclusion: A Word of Caution	433
	References	435
 <i>Index</i>		441

Intrinsic and Neural Control of Cardiac Function

Regulation of Myocardial Contractility

DOUGLAS F. MUNCH and JAMES M. DOWNEY

I. Contractility Defined	4
II. Neural Regulation of Cardiac Contractility	7
A. Sympathetic and Parasympathetic Effects	8
B. Baro- and Chemoreceptors	13
III. Humoral Regulation of Contractility	15
IV. Autoregulation	17
A. The Anrep Effect	18
B. The Bowditch Effect	19
References	20

The regulation of cardiac contractility covers a very broad area of physiologic knowledge. Since volumes have been written about individual regulatory mechanisms, an overview is all that we can hope to accomplish in these few pages. No introductory chapter on the regulation of myocardial contractility would be complete without first defining the meaning of the term "contractility." A theoretical definition will be presented here to facilitate the discussion of the factors involved in the regulation of contractility.

The regulation of myocardial contractility will be presented in three primary areas. First, the action of the sympathetic and parasympathetic autonomic nervous system, their neural transmitters, and the influence of physiologic receptor reflexes (baroreceptors and chemoreceptors) will be reviewed in the section concerning neural regulation of contractility. Second, humoral agents such as epinephrine and cortisol may play an important role in the regulation of cardiac performance. A model that describes the interactions of these agents with heart performance will be developed. Finally, intrinsic autoregulatory mechanisms that

may play a role in control of the heart's response to increases in afterload (the Anrep effect) and heart rate (the Bowditch effect) will be presented.

I. CONTRACTILITY DEFINED

Since Starling's statement of "the law of the heart" in 1918, great interest and energy has been directed toward evaluating and measuring the performance of cardiac muscle. Classically, Starling's law states that the energy output during contraction of heart muscle increases as the initial muscle length increases (Starling, 1918). Factors that are not related to changes in initial length can also vary the force generation of cardiac muscle. Though many factors have been identified, they all appear to act by changing the functional interaction between the actin and the myosin molecules. This has led investigators to seek a common index that will evaluate the functional state of these molecules at any given moment, the so-called "contractility." The difficulty arises in finding an index that separates the contribution due to initial length changes from those related to the "contractile state."

Contractility indices may be sensitive to either the absolute contractile state of a given heart or merely to changes in contractility, the latter task being considerably simpler than the former. All of our present methods for assessing contractility involve measuring one or more of the mechanical properties of the heart muscle. According to Sonnenblick (1965), there are four critical parameters which must be taken into account. These include the force of contraction, the velocity of contraction, the length of the muscle, and the time course of these variables during the activation period. When pooled together, the individual relationships between velocity, length (or volume), and load (or pressure) generate a surface as shown in Fig. 1. Activation of the contractile elements begins at point A, which represents the end of diastole.

Isovolumetric pressure generation continues through the peak of the active state, B, to the beginning of ejection at C, where the aortic valve opens. The ventricular ejection phase of the cardiac cycle continues to point D where the aortic valve closes, and ventricular volume is at a minimum. Finally, isovolumetric relaxation occurs from point D to E. Any change in the ionic or chemical environment will alter the interaction between myosin and actin, and therefore the contractility changes. Such a change in contractility would alter the relationships between the velocity-length, velocity-load, and length-load relationships, and a new surface would result (Sonnenblick, 1965).

Although the three-dimensional representation of the contractility surface appears to be an elegant method for measuring contractility, it is not presently possible to obtain all of the necessary data to construct such a surface in either the clinical setting or in the animal laboratory. Fortunately, however, certain




Fig. 1. The relationship among the parameters of velocity-muscle length-load forms a three-dimensional surface upon which the sequence of the cardiac cycle may be traced. Systole begins at point A. The velocity of the isovolumetric contraction increases to point B where velocity of the contraction declines while force continues to build. Ejection starts at point C, continues along the surface and ends at D. The path from D to E represents isovolumetric relaxation. (Modified from Sonnenblick, 1965, *Fed. Proc., Fed. Am. Soc. Exp. Biol.* **24**, 1396-1409.)

portions of these curves contain information concerning the contractile state and do lend themselves to laboratory measurement.

One of the earliest attempts at a practical index of contractility was to describe the relationship between stroke volume or cardiac output and ventricular volume (Patterson *et al.*, 1914). This technique takes advantage of the fact that stroke volume is a function of the contractile state. Since the influence of initial length is defined by the curve, any shift in the curve should denote a change in contractility. Unfortunately, stroke volume and cardiac output are not solely a function of the contractile state and ventricular filling, as they are affected by heart rate and ventricular afterload. Because stroke volume and afterload are inversely related, Sarnoff (1955) suggested that a better index of contractility could be derived by using stroke work (stroke volume \times afterload). The product of stroke volume and afterload is relatively constant for any inotropic state and was less influenced by heart rate yet is responsive to changes in contractility induced by inotropic agents (Sarnoff *et al.*, 1964), and coronary ischemia (Sarnoff, 1955). However, the ventricular function curve described by Sarnoff is also sensitive to changes in afterload (Sagawa, 1967). Recognizing this afterload dependence,